Effectiveness of Carboplatin and Paclitaxel in Metastatic Melanoma
Author Information
Author(s): Annette Pflugfelder, Thomas K. Eigentler, Ulrike Keim, Benjamin Weide, Ulrike Leiter, Kristian Ikenberg, Mark Berneburg, Claus Garbe
Primary Institution: University Hospital Tuebingen
Hypothesis
Can carboplatin and paclitaxel improve survival in patients with metastatic melanoma?
Conclusion
A subgroup of patients with metastatic melanoma achieved disease control under carboplatin and paclitaxel therapy, which may be associated with a survival benefit despite considerable toxicity.
Supporting Evidence
- 20 patients received CP as first-line treatment, while 41 had prior systemic therapy.
- Median overall survival was 31 weeks, with 60 out of 61 patients dying after a median follow-up of 7 months.
- Partial responses were noted in 4.9% of patients, and stable disease in 23%.
Takeaway
This study looked at how well two drugs, carboplatin and paclitaxel, work for people with a serious skin cancer called metastatic melanoma. Some patients did better, but the treatment can also cause a lot of side effects.
Methodology
Retrospective evaluation of patient data treated with carboplatin and paclitaxel between October 2005 and December 2007.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study is retrospective and may not account for all variables affecting treatment outcomes.
Participant Demographics
Median age was 53 years, with 56% male and 44% female participants.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website